IMpower130: PFS and safety of adding atezolizumab to first-line NSCLC therapy

(4:31)

PFS Improvement Seen in IMpower132 for NSCLC

(1:27)

IMpower130 Trial of Carbo/Nab-Pac +/- Atezo: Does this Positive Trial Change Management? (BMIC-071)

(9:59)

IMpassion130: Design and Preliminary Efficacy

(2:51)

Palbociclib shows improved PFS but not improved OS for ER+ HER2- mBC patients

(6:38)

Atezolizumab with chemotherapy improves PFS in squamous NSCLC

(3:28)

Looking at the IMpower Data in NSCLC

(3:18)

The IMpassion130 Trial in Metastatic Triple-Negative Breast Cancer

(1:16)

Results from the IMpassion 130 trial treating metastatic breast cancer

(4:56)

Treatment Approach After IMpower150 Regimen

(4:18)

IMPower150: Implications for the Treatment of NSCLC

(6:51)

Expanding the NSCLC Armamentarium: IMpower131

(2:12)

PD-1 Inhibitors in NSCLC: Combination or Monotherapy

(5:27)

Choosing Between Atezolizumab and Pembrolizumab in Lung Cancer

(3:1econd)

Optimizing Immunotherapy Combination Strategies for Metastatic NSCLC: From Evidence to Practice

(36:32)

Treating Ovarian Cancer With a PFI Less Than 6 Months

(3:48)

Real-world experience of Impower150 regimen for EGFR+ NSCLC

(1:33)

What Did We Learn From IMpower010 in Resectable NSCLC? - Medpage Today

(21:2)

IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma

(7:21)